We are live on ! Find out more
ENZ

Enzo Biochem, Inc.

Delisted

ENZ was delisted on the 17th of April, 2025.

63 hedge funds and large institutions have $55.3M invested in Enzo Biochem, Inc. in 2014 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 6

59% more capital invested

Capital invested by funds: $34.8M → $55.3M (+$20.5M)

26% more funds holding

Funds holding: 5063 (+13)

7% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 14

51% less call options, than puts

Call options by funds: $159K | Put options by funds: $325K

Holders
63
Holders Change
+13
Holders Change %
+26%
% of All Funds
1.82%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
19
Increased
13
Reduced
14
Closed
6
Calls
$159K
Puts
$325K
Net Calls
-$166K
Net Calls Change
+$16K
Name Holding Trade Value Shares
Change
Change in
Stake
Dimensional Fund Advisors
1
Dimensional Fund Advisors
Texas
$8.15M -$36.1K -10,544 -0.5%
ClearBridge Investments
2
ClearBridge Investments
New York
$4.76M -$85.1K -24,815 -2%
BIT
3
BlackRock Institutional Trust
California
$4.56M +$736K +214,781 +24%
FLAM
4
First Light Asset Management
Minnesota
$4.38M +$3.61M +1,053,702 New
Millennium Management
5
Millennium Management
New York
$4.09M -$778K -227,115 -19%
Vanguard Group
6
Vanguard Group
Pennsylvania
$4.02M +$405K +118,186 +14%
CCM
7
Corsair Capital Management
New York
$2.67M -$15.7K -4,594 -0.7%
EI
8
EAM Investors
California
$2.14M +$1.77M +515,191 New
PRC
9
Platte River Capital
Colorado
$1.96M -$206K -60,000 -11%
TC
10
TFS Capital
Pennsylvania
$1.93M +$1.59M +464,044 New
Renaissance Technologies
11
Renaissance Technologies
New York
$1.86M +$350K +102,244 +30%
PA
12
Perceptive Advisors
New York
$1.58M +$1.3M +380,000 New
Allianz Asset Management
13
Allianz Asset Management
Germany
$1.58M +$1.3M +379,612 New
CPIM
14
Columbia Partners Investment Management
Virginia
$1.2M +$988K +288,173 New
BCM
15
Bridgeway Capital Management
Texas
$999K
CCT
16
Chemung Canal Trust
New York
$907K
WA
17
Whitebox Advisors
Minnesota
$753K +$621K +181,100 New
Geode Capital Management
18
Geode Capital Management
Massachusetts
$620K +$215K +62,622 +72%
Goldman Sachs
19
Goldman Sachs
New York
$553K -$52.6K -15,351 -10%
AA
20
Ancora Advisors
Ohio
$541K -$68.6K -20,000 -13%
AAP
21
Ardsley Advisory Partners
Connecticut
$520K +$137K +40,000 +47%
PAM
22
Panagora Asset Management
Massachusetts
$475K +$391K +114,146 New
Charles Schwab
23
Charles Schwab
California
$451K +$119K +34,700 +47%
Northern Trust
24
Northern Trust
Illinois
$433K +$27.2K +7,932 +8%
Citadel Advisors
25
Citadel Advisors
Florida
$433K +$283K +82,585 +385%

ENZ Hedge Fund Activity: Q1 2014 in Review

63 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q1 2014, worth a combined $55.3M — up 59% from $34.8M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ENZ positions and 6 closed out — a net gain of 13 holders — while 13 added to existing stakes and 14 trimmed.

The largest buyer was First Light Asset Management, opening a new position worth an estimated $3.61M. The largest seller was RA Capital Management, exiting entirely with an estimated $6.62M sold.

  • 63 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q1 2014, up from 50 in Q4 2013.
  • Funds reported $55.3M of Enzo Biochem, Inc. stock for Q1 2014, up 59% quarter-over-quarter.
  • 19 funds opened new Enzo Biochem, Inc. positions in Q1 2014 and 6 closed out, a net change of +13 holders.
  • The largest Enzo Biochem, Inc. buyer in Q1 2014 was First Light Asset Management, an estimated $3.61M added.
  • The largest Enzo Biochem, Inc. seller in Q1 2014 was RA Capital Management, an estimated $6.62M sold.

Based on aggregated 13F filings for Q1 2014.